Cancer is the second leading cause of death globally, requiring urgent advancements in diagnosis and treatment to keep pace with the rising incidence.
Emerging biopharmaceutical companies are increasingly dominating the oncology clinical trial landscape, reflecting their growing importance in cancer research.